Business Wire

JAPAN-SANITARY-EQUIP-IND

26.7.2022 04:02:07 CEST | Business Wire | Press release

Share
The Japan Sanitary Equipment Industry Association: Warm Water Spray Seat Shipments Reach 100 Million Units in Japan

The Japan Sanitary Equipment Industry Association, which is composed of Japanese companies engaged in the manufacturing of toilets (Headquarters: Nagoya, Aichi, Japan. President: Noriaki Kiyota [President & Representative Director of TOTO Ltd.], hereinafter “Association”) is proud to announce that the number of warm water spray seat shipments since the industry began tracking statistics (1987) has reached 100 million units as of June 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005331/en/

The Road to 100 Million Units

The start of importation and sale of toilets and toilet seats with warm-water washing functionality into Japan in 1964 sparked major changes of “washing bottoms” in Japanese toilets. At first, sales were targeted towards medical facilities, and use was not widespread. Later, domestic production began, and companies launched initiatives including product development and improvement, and sales promotions to encourage use in common households. Eventually, more Japan residents grew to recognize these products after a TV commercial in 1982. Once people experienced the comfort of a warm toilet seat and the refreshing satisfaction of rear cleansing, they were unable to live without it. Good reputations spread, and these products finally became accepted by the general public.

Association member companies have been working continuously to evolve these products and to promote further use, by making new proposals and implementing updates that reflect consumer needs across multiple aspects, including function, comfort, hygiene, design, and energy efficiency. Currently in 2022, usage rates in general households have surpassed 80%, which means that it can finally be said that these products are estimated to be used in the majority of general households with flushable toilets. Likewise, because warm water spray seats have a good reputation for comfort, they have also been widely adopted for use in public places such as office buildings, commercial facilities, hotels, trains, and train stations.

Must-Have Item for Japanese Bathrooms

According to an awareness survey conducted by the Association in 2022 among warm water spray seat users in Japan, the main reason for use was “It’s sanitary and feels good to use.” In addition, 97% of the respondents would like to continue to use the warm-water washing toilet seats, indicating that once they use them, they find it so comfortable that they will not want to give them up.

Meanwhile, outside of Japan, demands are growing in other countries across the Americas, Europe, Asia, and the Middle East in recent years as interest in hygiene continues to rise, and the international market for warm water spray seats continues to expand every year. In particular, a sudden rise in demand was seen in North America in 2020, stoking anticipation for wider usage in the near future.

The Association and its members, Japanese manufacturers of warm water spray seats, are dedicated to making real improvements in restroom culture worldwide through the wider usage of sanitary and comfortable warm water spray seats in every country.

Awareness Survey for Warm Water Spray Seat Users

Survey Method: Online questionnaire
Survey Targets: Users of warm-water washing toilet seats, aged 10 to 79, living in Japan, 150 respondents for each age group, total of 2,100 respondents
Survey Period: February 4, 2022 (Friday) to February 7, 2022 (Sunday)

[ Survey Results Summary ]

The main reason for use was “It’s sanitary and feels good to use.”
When asked why they use warm water spray seats, most respondents said “It removes waste well and keeps me clean” (82%) and nearly half of respondents said “It feels good and refreshing” (48%).

97% of respondents said “I want to continue using it.”
Regarding their intention to continue the use of warm-water toilet seats in the future, 86% of respondents said they would like to continue to use them, and 11% said they would rather continue to use them.

Learn More About the Japan Sanitary Equipment Industry Association

The Japan Sanitary Equipment Industry Association is an industry organization made up of toilet equipment manufacturers that handle products such as sanitary fixtures (large and small toilets) and warm-water washing toilet seats.
The Japan Sanitary Equipment Industry Association operates the JAPAN TOILET INFORMATION website, which is dedicated to providing information on toilet conditions in Japan (usage, signage, etc.) for foreign visitors to Japan.
(https://www.sanitary-net.com/utsukushitoilet/en/ )

[ Member Companies (As of June 2022, in alphabetical order) ]

Aisin Corporation, Asahi Eito Co., Ltd., Janis Ltd., Lixil Corporation, Panasonic Holdings Corporation, SAN-EI Faucet Mfg Co., Ltd, Toshiba Lifestyle Products & Services Corporation, TOTO Ltd.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye